^
    9d
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | Trial completion date: Jan 2028 --> Aug 2028 | Trial primary completion date: Aug 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • IMNN-001
    2ms
    Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings. (PubMed, Expert Opin Investig Drugs)
    IMNN-001 gene therapy could add clinically meaningful IL-12-driven immunotherapy to newly diagnosed ovarian cancer patients. IMNN-001 holds promise for synergistic combinations with immunotherapies requiring intrinsic immune activity.
    Review • Journal • IO biomarker
    |
    IFNG (Interferon, gamma)
    |
    IMNN-001
    3ms
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Imunon | N=50 --> 30
    Enrollment change
    |
    carboplatin • paclitaxel • IMNN-001
    10ms
    OVATION-3: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=500, Recruiting, Imunon | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lynparza (olaparib) • carboplatin • paclitaxel • Zejula (niraparib) • IMNN-001
    1year
    OVATION-3: Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, Imunon
    New P3 trial
    |
    Lynparza (olaparib) • carboplatin • paclitaxel • Zejula (niraparib) • IMNN-001
    1year
    Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Imunon | Trial primary completion date: Dec 2024 --> Jul 2024
    Trial primary completion date
    |
    carboplatin • paclitaxel • IMNN-001
    over1year
    Study of IMNN-001 (also Known As GEN-1) with NACT for Treatment of Ovarian Cancer (OVATION 2) (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Imunon | Trial completion date: Dec 2024 --> Nov 2025
    Trial completion date • Combination therapy • Metastases
    |
    carboplatin • paclitaxel • IMNN-001
    over2years
    MRD: Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Imunon | Phase classification: P2 --> P1/2
    Phase classification
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • IMNN-001
    3years
    Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2) (clinicaltrials.gov)
    P1/2, N=130, Active, not recruiting, Imunon | Trial primary completion date: Feb 2023 --> Dec 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    carboplatin • paclitaxel • IMNN-001
    3years
    Efficacy of Gen-1, an interleukin-12 immune gene therapy, at different dose frequencies (AACR 2023)
    Once every 2-week dosing of GEN-1 in human studies is warranted. Future combination studies of Gen-1 with immune checkpoint inhibitors will evaluate the safety and efficacy of this regimen.
    Clinical • Gene therapy
    |
    GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    IMNN-001
    3years
    MRD: Phase II GEN-1 on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Imunon
    New P2 trial • Combination therapy • Metastases
    |
    GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • IMNN-001
    over3years
    Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. (PubMed, JCO Clin Cancer Inform)
    Comparing results of a single-arm early-phase trial to those of a rigorously matched HCT ECA yielded insights regarding comparative efficacy prior to a randomized controlled trial. The effect size estimate itself informed both the decision to continue development and the randomized phase II trial (ClinicalTrials.gov identifier: NCT03393884) sample size. The work illustrates the potential of HCT data to inform drug development.
    Journal
    |
    GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    IMNN-001